BRIEF published on 10/10/2025 at 22:16, 8 months 17 days ago La FDA approuve UZEDY pour le traitement du trouble bipolaire de type I chez l'adulte Approbation De La FDA Traitement De Santé Mentale UZEDY Trouble Bipolaire I Risperidone
BRIEF published on 10/10/2025 at 22:16, 8 months 17 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 8 months 17 days ago Informations privilégiées / Autres communiqués La FDA approuve l’extension d’indication de UZEDY® pour le traitement de patients atteints de trouble bipolaire de type I par Teva Pharmaceuticals et Medincell FDA Medincell Teva Pharmaceuticals UZEDY Traitement Bipolaire
PRESS RELEASE published on 10/10/2025 at 22:11, 8 months 17 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 9 months 10 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
BRIEF published on 09/17/2025 at 14:05, 9 months 10 days ago Medincell et Teva présentent les données de phase 3 sur l'olanzapine LAI Essai De Phase 3 Traitement De La Schizophrénie Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 9 months 10 days ago Informations privilégiées / Autres communiqués Teva et Medincell présenteront les résultats de phase 3 de l'Olanzapine LAI à Psych Congress 2025, préparant le lancement du traitement de la schizophrénie avec Teva Schizophrénie Phase 3 Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 9 months 10 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 9 months 16 days ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
BRIEF published on 09/12/2025 at 07:35, 9 months 16 days ago Medincell nomme trois nouveaux membres au conseil d'administration Innovation Biopharmaceutique Direction Nominations Au Conseil D'administration Medincell
Published on 06/27/2026 at 16:50, 18 hours 4 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 9 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 10 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 11 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 12 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 10 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 10 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 11 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 11 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 11 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
